Structural and Functional Studies of Rhodopsin and G-Protein Coupled Receptor Kinases
视紫红质和 G 蛋白偶联受体激酶的结构和功能研究
基本信息
- 批准号:10012941
- 负责人:
- 金额:$ 36.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-04-01 至 2021-01-31
- 项目状态:已结题
- 来源:
- 关键词:ARNT geneAdoptedAgonistAntibodiesArchitectureArrestinsBindingBinding SitesBiochemicalBiological AssayBiological ModelsCell Surface ReceptorsCellsChemicalsCollaborationsCommunicationComplexCouplingCryoelectron MicroscopyCrystallizationDiseaseDisulfidesDrug TargetingFamilyFutureG Protein-Coupled Receptor SignalingG protein coupled receptor kinaseG-Protein-Coupled ReceptorsGRK1 geneGRK5 geneGTP-Binding ProteinsGenetic PolymorphismGoalsHeart DiseasesHomeostasisHumanKnowledgeLigandsLipidsMalignant NeoplasmsMass Spectrum AnalysisMediatingModelingMolecular ConformationMutationNatureNegative StainingNeurodegenerative DisordersPathway interactionsPhosphorylationPhosphotransferasesPhysiologicalProcessReceptor SignalingResolutionRhodopsinSignal TransductionSignaling ProteinStructureTechnologyTherapeuticTimebasebiophysical techniquescrosslinkdesigndrug discoveryinsightinterestprotein activationreceptorreceptor bindingscreeningside effectsmall moleculesuccess
项目摘要
PROJECT SUMMARY/ABSTRACT
Humans have more than 800 different G protein-coupled receptors (GPCRs), which form the
largest family of cell-surface receptors and account for ~30% of all therapeutic drug targets.
Upon activation by agonists, GPCRs adopt distinct activated states that allow them to couple
either to G proteins, to initiate G protein-mediated signaling, or to GPCR kinases (GRKs), which
phosphorylate GPCRs to enable their interactions with arrestins to terminate G protein
activation and initiate arrestin-mediated signaling. While physiological agonists initiate both G
protein- and arrestin-mediated signaling, often only one of the two pathways is therapeutically
beneficial, while the other pathway is responsible for unwanted side effects. Given the
importance of GPCRs as drug targets, there is huge interest in developing “biased” GPCR
agonist that signal predominantly through only one of the two pathways. However, the critical
barrier for rationally developing biased agonist is the limited information on how GRKs interact
with GPCRs and the complete absence of any high resolution GPCR/GRK structure. Crystal
and cryo-EM structures of four GPCRs in complex with G proteins and of one GPCR in complex
with an arrestin have provided an emerging understanding of the receptor conformations
required for G protein and arrestin coupling, yet a mechanistic understanding of how GRKs bind
and phosphorylate GPCRs have remained elusive due to the highly transient nature of this
interaction. The objective of this proposal is to bridge this critical gap in knowledge by
exploiting the interaction between rhodopsin and GRK1 as a paradigm to determine the
mechanistic and structural basis of the targetable interaction between GPCRS and GRKs.
SIGNIFICANCE: Completion of the proposed aims will reveal the first mechanistic basis of
GRK/GPCR recognition and reveal the GPCR/GRK conformation that enables GRK binding and
receptor phosphorylation. This information is of paramount importance for the rational design of
therapeutic biased agonists for the treatment of a broad spectrum of diseases.
项目摘要/摘要
人类具有800多种不同的G蛋白偶联受体(GPCR),它们形成了
最大的细胞表面受体家族占所有治疗药物靶标的30%。
激动剂激活后,GPCR采用不同的激活状态,使他们能够搭配
要么G蛋白,要启动G蛋白介导的信号传导,或者启动GPCR激酶(GRKS),该信号(GRKS)
磷酸化GPCR可以使其与逮捕蛋白的相互作用终止G蛋白
激活并引发抑制蛋白介导的信号传导。当身体激动剂启动两个g
蛋白质和逮捕蛋白介导的信号传导,通常只有两种途径中只有一种
有益的,而另一条途径则负责有害的副作用。鉴于
GPCR作为药物靶标的重要性,对发展“有偏见” GPCR具有很大的兴趣
激动剂主要通过两种途径之一发出信号。但是,关键
合理发展的偏见激动剂的障碍是GRK相互作用的有限信息
GPCR和完全没有任何高分辨率GPCR/GRK结构。水晶
和与G蛋白和复合物中的一个GPCR复合物的四个GPCR的冷冻EM结构
逮捕蛋白提供了对接收器构象的新兴理解
G蛋白和阻止蛋白偶联所需
由于高度短暂的性质,磷酸化GPCR仍然难以捉摸
相互作用。该提议的目的是通过
利用视紫红质和grk1之间的相互作用作为范式来确定
GPCR和GRK之间可靶向相互作用的机械和结构基础。
意义:拟议目标的完成将揭示第一的机械基础
grk/gpcr识别并揭示GPCR/GRK构象,使GRK结合和
受体磷酸化。对于合理设计,此信息至关重要
治疗偏见的激动剂治疗多种疾病。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Karsten Melcher其他文献
Karsten Melcher的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Karsten Melcher', 18)}}的其他基金
Structural interrogation of allosteric AMPK regulation
变构 AMPK 调节的结构探究
- 批准号:
8584776 - 财政年份:2013
- 资助金额:
$ 36.58万 - 项目类别:
Structural interrogation of allosteric AMPK regulation
变构 AMPK 调节的结构探究
- 批准号:
8831699 - 财政年份:2013
- 资助金额:
$ 36.58万 - 项目类别:
Structural and functional analysis of a dynamic ABA signaling complex
动态 ABA 信号复合物的结构和功能分析
- 批准号:
8346496 - 财政年份:2012
- 资助金额:
$ 36.58万 - 项目类别:
Structural and functional analysis of a dynamic ABA signaling complex
动态 ABA 信号复合物的结构和功能分析
- 批准号:
8500400 - 财政年份:2012
- 资助金额:
$ 36.58万 - 项目类别:
相似国自然基金
采用新型视觉-电刺激配对范式长期、特异性改变成年期动物视觉系统功能可塑性
- 批准号:32371047
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
破解老年人数字鸿沟:老年人采用数字技术的决策过程、客观障碍和应对策略
- 批准号:72303205
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
通过抑制流体运动和采用双能谱方法来改进烧蚀速率测量的研究
- 批准号:12305261
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
采用多种稀疏自注意力机制的Transformer隧道衬砌裂缝检测方法研究
- 批准号:62301339
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
政策激励、信息传递与农户屋顶光伏技术采用提升机制研究
- 批准号:72304103
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
The role of PPARγ in astrocyte pathobiology after exposure to repetitive mild traumatic brain injury
PPARγ 在重复性轻度脑外伤后星形胶质细胞病理学中的作用
- 批准号:
10739968 - 财政年份:2023
- 资助金额:
$ 36.58万 - 项目类别:
Mentoring the next generation of researchers at the intersection of opioid use disorder and chronic pain
指导下一代研究人员研究阿片类药物使用障碍和慢性疼痛的交叉点
- 批准号:
10663642 - 财政年份:2023
- 资助金额:
$ 36.58万 - 项目类别:
CLEC7A in microglia biology and Alzheimer's disease
CLEC7A 在小胶质细胞生物学和阿尔茨海默病中的作用
- 批准号:
10659940 - 财政年份:2023
- 资助金额:
$ 36.58万 - 项目类别:
Development of the OpiAID strength band platform
OpiAID 力量带平台的开发
- 批准号:
10684399 - 财政年份:2023
- 资助金额:
$ 36.58万 - 项目类别:
Developing a computational platform for induced-fit and chemogenetic drug design
开发诱导拟合和化学遗传学药物设计的计算平台
- 批准号:
10680745 - 财政年份:2023
- 资助金额:
$ 36.58万 - 项目类别: